Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424486 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL12463068 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL22631620 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL17399388 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL23100945 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL23101821 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL736043 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL13243111 | 0.88 | LMNA (0.46) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL16727365 | 0.88 | MAPK1 (0.46) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL14310687 | 0.88 | MAPK1 (0.46) | CYP2C9LMNASLC6A2SLC6A3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023150203-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20210078958-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2021-03-18 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-7786299-B2 | Methods for treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-7759485-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7750152-B2 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | CYP2C9 3488/4885LMNA 1800/4885SLC6A2 2851/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | CYP2C9 3488/4885LMNA 1800/4885SLC6A2 2851/4885 |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | PLK4, TK1, POLK | CYP2C9 3584/4885LMNA 1357/4885SLC6A2 3503/4885 |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CYP2C9 2355/4885LMNA 3791/4885SLC6A2 1034/4885 |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | CYP2C9 4175/4885LMNA 1168/4885SLC6A2 3624/4885 |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | CYP2C9 956/4885LMNA 4112/4885SLC6A2 998/4885 |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | QDPR, DHPS, DHODH | CYP2C9 129/4885LMNA 1883/4885SLC6A2 3989/4885 |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | CYP2C9 1407/4885LMNA 4325/4885SLC6A2 4837/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | CYP2C9 221/4885LMNA 2318/4885SLC6A2 3826/4885 |
| US-20210078958-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | ABL1, ERBB2, FLT3 | CYP2C9 129/4885LMNA 4251/4885SLC6A2 1028/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | CYP2C9 3488/4885LMNA 1800/4885SLC6A2 2851/4885 |
| US-20080293944-A1 | Piperazinyl Compounds | QDPR, DHPS, DPYD | CYP2C9 205/4885LMNA 1790/4885SLC6A2 4345/4885 |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | PTPN5, PTPN7, PTPN1 | CYP2C9 4046/4885LMNA 4843/4885SLC6A2 4186/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | CYP2C9 3488/4885LMNA 1800/4885SLC6A2 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.